Pulmonx (LUNG) Earnings
In the quarter ended September 2026, Pulmonx had revenue of $23M, up 6.2% on a year earlier, and diluted EPS of -0.19.
Summary
On October 27, 2026 it reported EPS of -0.19 against an estimate of -0.26 (beat).
Report dates
| Report | Date | Time | EPS estimate | EPS reported | Result |
|---|---|---|---|---|---|
| Last | Tue Oct 27, 2026 | After close | -0.26 | -0.19 | Beat |
Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.
Quarterly results
The last 12 quarters from Pulmonx's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | $23M | +6.2% | -0.19 | — | -32.8% | 2026-11-03 |
| Jun 30, 2026 | $23M | -4.6% | -0.24 | — | -39.8% | 2026-08-04 |
| Mar 31, 2026 | $21M | -8.7% | -0.33 | — | -62.9% | 2026-05-04 |
| Dec 31, 2025 | $23M | -4.9% | — | — | -43.8% | 2026-03-10 |
| Sep 30, 2025 | $22M | +5.5% | -0.34 | — | -66.9% | 2025-11-12 |
| Jun 30, 2025 | $24M | +14.8% | -0.38 | — | -62.0% | 2025-08-01 |
| Mar 31, 2025 | $23M | +19.5% | -0.36 | — | -64.6% | 2025-05-02 |
| Dec 31, 2024 | $24M | +23.3% | — | — | -56.5% | 2025-02-25 |
| Sep 30, 2024 | $20M | +15.4% | -0.36 | — | -69.3% | 2024-11-01 |
| Jun 30, 2024 | $21M | +20.9% | -0.39 | — | -75.2% | 2024-08-02 |
| Mar 31, 2024 | $19M | +29.7% | -0.36 | — | -77.1% | 2024-05-03 |
| Dec 31, 2023 | $19M | +25.0% | — | — | -72.2% | 2024-02-27 |
Questions about Pulmonx
Did Pulmonx beat earnings estimates?
In its report on October 27, 2026, Pulmonx beat the EPS estimate: -0.19 reported against -0.26 expected.
How did Pulmonx do last quarter?
In the quarter ended September 2026, Pulmonx had revenue of $23M, up 6.2% on a year earlier, and diluted EPS of -0.19.
From Pulmonx's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.